The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus

Current Medical Research and Opinion
Sharash ShettyCraig I Coleman

Abstract

To assess the magnitude of difference in all-cause healthcare resource utilization (HCRU) and costs between patients with type 2 diabetes mellitus (T2DM) who died from a cardiovascular disease (CVD)-related cause in the year preceding death vs. those who did not die during this same period. A large US administrative claims database was used to identify patients with T2DM who died of a CVD-related cause from July 2012 to April 2015. These patients were matched 1:1 to patients with T2DM who did not die, using direct matching methods. HCRU and costs were assessed in each of the four quarters (Q4: 12-10 months; Q3: 9-7 months; Q2: 6-4 months; and Q1: 3-0 months) prior to death and compared between patient cohorts using paired t-tests and McNemar's tests. A final matched cohort of 7648 patients who died and 7648 patients who did not die were identified. A significantly higher proportion of patients who died utilized inpatient services vs. those who did not die (Q4: 12.6% vs. 4.6%, p < .001; Q3: 14.6% vs. 4.6%, p < .001; Q2: 17.6% vs. 5.5%, p < .001; and Q1: 65.0% vs. 10.1%, p < .001). In addition, patients who died incurred significantly higher all-cause costs (Q4: $8882 vs. $3970, p < .001; Q3: $10,462 vs. $3661, p < .001; Q2: $12,...Continue Reading

References

May 1, 1992·American Journal of Epidemiology·S WacholderJ S Mandel
Mar 23, 2002·Annual Review of Public Health·Thomas LumleyLu Chen
Jul 20, 2006·American Journal of Medical Quality : the Official Journal of the American College of Medical Quality·Leif I SolbergPatrick J O'Connor
Sep 28, 2010·Statistical Science : a Review Journal of the Institute of Mathematical Statistics·Elizabeth A Stuart
Oct 13, 2010·Archives of Internal Medicine·Kathleen T UnroeLesley H Curtis
Mar 8, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Aug 21, 2013·American Journal of Preventive Medicine·Xiaohui ZhuoThomas J Hoerger
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Apr 3, 2015·Circulation. Heart Failure·Shannon M DunlayVéronique L Roger
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Nov 25, 2016·Journal of Managed Care & Specialty Pharmacy·Engels N ObiAylin Altan
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.